Long-term follow up of selinexor maintenance in patients with TP53 wt advanced or recurrent endometrial cancer: A pre-specified subgroup analysis from the phase 3 ENGOT-EN5/GOG-3055/SIENDO study

• Published in: Journal of clinical oncology Vol. 41; no. 36_suppl; p. 427956
• Main Authors: Slomovitz, Brian M., Perez-Fidalgo, Jose Alejandro, Hamilton, Erika P., Valabrega, Giorgio, Van Gorp, Toon, Sehouli, Jalid, Klat, Jaroslav, Levy, Tally, Welch, Stephen, Richardson, Debra L., Guerra Alia, Eva Maria, Scambia, Giovanni, Henry, Stephanie, Wimberger, Pauline, Martinez, Jeronimo, Monk, Bradley J., Kalyanapu, Pratheek, Raza Mirza, Mansoor, Makker, Vicky, Vergote, Ignace
• Format: Journal Article
• Language: English
• Published: 20.07.2023

427956 Background: Molecular characterization is important to inform treatment decisions for patients with endometrial cancer (EC). Wild type TP53 ( TP53wt) is found in ~75% of newly diagnosed EC and 50% of advanced/recurrent tumors; there are no specific targeted therapies available for patients wi...